Skip to content
2000
Volume 26, Issue 2
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Piperaquine is an important partner drug in artemisinin-based combination therapy, which is highly effective for the treatment of uncomplicated malaria. Several studies have been reported on its pharmacokinetic profiles in different populations, as well as its bioanalytical methods. Piperaquine shows a very large volume of distribution (up to 877 l/kg), a low oral clearance (0.3-1.9 l/h/kg), and an extremely long terminal elimination half-life (up to 30 days) in both healthy volunteers and malarial patients. Piperaquine metabolism is primarily mediated by CYP3A4, and to a lesser extent by CYP2D6 and CYP2C8. The oral bioavailability of piperaquine can be influenced by the consumption of high-fat food. The pharmacokinetics of piperaquine is affected by body weight, age, and pregnancy. Piperaquine has limited clinically relevant interactions with most commonly prescribed drugs. Plasma has been the most commonly studied matrix, and the most used pretreatment techniques involve protein precipitation. HPLC-UV and HPLC-MS/MS are usually used for the quantification of piperaquine in biological samples with researchers seeking a balance between affordability and sensitivity. This review summarizes the analytical assays used for the quantification of piperaquine in biological samples and its pharmacokinetic properties, with particular attention to information on food–drug interactions, drug-drug interactions, and pharmacokinetic characteristics in special populations, including pregnant women and children.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002374755250613064601
2025-06-27
2026-01-20

  • From This Site

    /content/journals/cdm/10.2174/0113892002374755250613064601
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. DailyJ.P. MinutiA. KhanN. Diagnosis, treatment, and prevention of malaria in the US.JAMA2022328546047110.1001/jama.2022.12366 35916842
     [Google Scholar]
  2. VenkatesanP. WHO world malaria report 2024.Lancet Microbe20256410107310.1016/j.lanmic.2025.101073 39923782
     [Google Scholar]
  3. Van Den HamK.M. BowerL.K. LiS. LorenziH. DoumboS. DoumtabeD. KayentaoK. OngoibaA. TraoreB. CromptonP.D. SchmidtN.W. The gut microbiome is associated with susceptibility to febrile malaria in Malian children.Nat. Commun.2024151952510.1038/s41467‑024‑52953‑8 39500866
     [Google Scholar]
  4. BarsosioH.C. WebsterJ. OmitiF. K’Oloo, A.; Odero, I.A.; Ojuok, M.A.; Odiwa, D.; Omondi, B.; Okello, E.; Dodd, J.; Taegtmeyer, M.; Kuile, F.O.; Lesosky, M.; Kariuki, S.; Hill, J. Delivery effectiveness of and adherence to intermittent preventive treatment for malaria in pregnancy with dihydroartemisinin–piperaquine with or without targeted information transfer or sulfadoxine–pyrimethamine in western Kenya: A three-armed, pragmatic, open-label, cluster-randomised trial.Lancet Glob. Health20241210e1660e167210.1016/S2214‑109X(24)00261‑4 39304238
     [Google Scholar]
  5. PasayC.J. RockettR. SekuloskiS. GriffinP. MarquartL. PeateyC. WangC.Y.T. O’RourkeP. ElliottS. BakerM. MöhrleJ.J. McCarthyJ.S. Piperaquine monotherapy of drug-susceptible Plasmodium falciparum infection results in rapid clearance of parasitemia but is followed by the appearance of gametocytemia.J. Infect. Dis.2016214110511310.1093/infdis/jiw128 27056954
     [Google Scholar]
  6. FerreiraL.T. CassianoG.C. AlvarezL.C.S. OkomboJ. CalitJ. FontinhaD. Gil-IturbeE. CoyleR. AndradeC.H. SunnerhagenP. BargieriD.Y. PrudêncioM. QuickM. CravoP.V. LeeM.C.S. FidockD.A. CostaF.T.M. A novel 4-aminoquinoline chemotype with multistage antimalarial activity and lack of cross-resistance with PfCRT and PfMDR1 mutants.PLoS Pathog.20242010e101262710.1371/journal.ppat.1012627 39471233
     [Google Scholar]
  7. SinghR. SinghR. SrihariV. MakdeR.D. Investigation unveiling new insights into the antimalarial mechanism of chloroquine: Role in perturbing nucleation events during heme to β-hematin transformation.ACS Infect. Dis.2023981647165710.1021/acsinfecdis.3c00278 37471056
     [Google Scholar]
  8. KeatingG.M. Dihydroartemisinin/Piperaquine.Drugs201272793796110.2165/11203910‑000000000‑00000 22515619
     [Google Scholar]
  9. DengC. WuW. YuanY. LiG. ZhangH. ZhengS. LiM. TanR. WangY. NadiaJ. FengD. LiD. WuZ. XuQ. LiC. WangZ. LiangY. DoehlJ.S.P. SuX. BacarA. Said AbdallahK. MohamedH. Msa MlivaA. WellemsT.E. SongJ. Malaria control by mass drug administration with artemisinin plus piperaquine on Grande Comore island, Union of Comoros.Open Forum Infect. Dis.2023103ofad07610.1093/ofid/ofad07636910690
     [Google Scholar]
  10. WallenderE. AliA.M. HughesE. KakuruA. JagannathanP. MuhindoM.K. OpiraB. WhalenM. HuangL. DuvalsaintM. LegacJ. KamyaM.R. DorseyG. AweekaF. RosenthalP.J. SavicR.M. Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children.Nat. Commun.2021121671410.1038/s41467‑021‑27051‑8 34795281
     [Google Scholar]
  11. TseE.G. KorsikM. ToddM.H. The past, present and future of anti-malarial medicines.Malar. J.20191819310.1186/s12936‑019‑2724‑z 30902052
     [Google Scholar]
  12. XieY. ZhangY. LinF. ChenX. XingJ. The effect of malaria-induced alteration of metabolism on piperaquine disposition in Plasmodium yoelii infected mice and predicted in malaria patients.Int. J. Antimicrob. Agents202464110720910.1016/j.ijantimicag.2024.107209 38761871
     [Google Scholar]
  13. TarningJ. LindegardhN. Quantification of the antimalarial piperaquine in plasma.Trans. R. Soc. Trop. Med. Hyg.2008102540941110.1016/j.trstmh.2008.02.011 18378269
     [Google Scholar]
  14. MaR. GuoD.X. LiH.F. LiuH.X. ZhangY.R. JiJ.B. XingJ. WangS.Q. Spectroscopic methodologies and molecular docking studies on the interaction of antimalarial drug piperaquine and its metabolites with human serum albumin.Spectrochim. Acta A Mol. Biomol. Spectrosc.201922211715810.1016/j.saa.2019.117158 31181505
     [Google Scholar]
  15. ChotsiriP. WhiteN.J. TarningJ. Pharmacokinetic considerations in seasonal malaria chemoprevention.Trends Parasitol.202238867368210.1016/j.pt.2022.05.003 35688778
     [Google Scholar]
  16. HungT.Y. DavisT.M.E. IlettK.F. KarunajeewaH. HewittS. DenisM.B. LimC. SocheatD. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria.Br. J. Clin. Pharmacol.200457325326210.1046/j.1365‑2125.2003.02004.x 14998421
     [Google Scholar]
  17. LiuH. ZhouH. CaiT. YangA. ZangM. XingJ. The metabolism of piperaquine to its antiplasmodial metabolites and their pharmacokinetic profiles in healthy volunteers.Antimicrob. Agents Chemother.2018628e00260e1810.1128/AAC.00260‑18 29784841
     [Google Scholar]
  18. HughesE. ImperialM. WallenderE. KajubiR. HuangL. JagannathanP. ZhangN. KakuruA. NatureebaP. MwimaM.W. MuhindoM. MwebazaN. ClarkT.D. OpiraB. NakalembeM. HavlirD. KamyaM. RosenthalP.J. DorseyG. AweekaF. SavicR.M. Piperaquine exposure is altered by pregnancy, HIV, and nutritional status in Ugandan women.Antimicrob. Agents Chemother.20206412e01013e0102010.1128/AAC.01013‑20 33020153
     [Google Scholar]
  19. AhmedT. SharmaP. GautamA. VarshneyB. KothariM. GangulyS. MoehrleJ.J. PaliwalJ. SahaN. BatraV. Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects.J. Clin. Pharmacol.200848216617510.1177/0091270007310384 18199893
     [Google Scholar]
  20. CharmanS.A. AndreuA. BarkerH. BlundellS. CampbellA. CampbellM. ChenG. ChiuF.C.K. CrightonE. KatneniK. MorizziJ. PatilR. PhamT. RyanE. SaundersJ. ShacklefordD.M. WhiteK.L. AlmondL. DickinsM. SmithD.A. MoehrleJ.J. BurrowsJ.N. AblaN. An in vitro toolbox to accelerate anti-malarial drug discovery and development.Malar. J.2020191110.1186/s12936‑019‑3075‑5 31898492
     [Google Scholar]
  21. LeeT.M.N. HuangL. JohnsonM.K. LizakP. KroetzD. AweekaF. ParikhS. In vitro metabolism of piperaquine is primarily mediated by CYP3A4.Xenobiotica201242111088109510.3109/00498254.2012.693972 22671777
     [Google Scholar]
  22. XieY. ZhangY. LiuH. XingJ. Metabolic retroversion of piperaquine (PQ) via hepatic cytochrome P450-mediated N-oxidation and reduction: Not an important contributor to the prolonged elimination of PQ.Drug Metab. Dispos.202149537938810.1124/dmd.120.000306 33674271
     [Google Scholar]
  23. TarningJ. BergqvistY. DayN.P. BergquistJ. ArvidssonB. WhiteN.J. AshtonM. LindegårdhN. Characterization of human urinary metabolites of the antimalarial piperaquine.Drug Metab. Dispos.200634122011201910.1124/dmd.106.011494 16956956
     [Google Scholar]
  24. YangA. ZangM. LiuH. FanP. XingJ. Metabolite identification of the antimalarial piperaquine in vivo using liquid chromatography–high‐resolution mass spectrometry in combination with multiple data‐mining tools in tandem.Biomed. Chromatogr.20163081324133010.1002/bmc.3689 26821381
     [Google Scholar]
  25. XingJ. ZhouH. ZhangL. JiJ. XieY. The effect of retroconversion metabolism of N-oxide metabolites by intestinal microflora on piperaquine elimination in mice, as well as in humans predicted using a PBPK model.Curr. Drug Metab.202324213113810.2174/1389200224666230320112429 36941813
     [Google Scholar]
  26. SimI.K. DavisT.M.E. IlettK.F. Effects of a high-fat meal on the relative oral bioavailability of piperaquine.Antimicrob. Agents Chemother.20054962407241110.1128/AAC.49.6.2407‑2411.2005 15917540
     [Google Scholar]
  27. ChinhN.T. QuangN.N. ThanhN.X. DaiB. TraversT. EdsteinM.D. Pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects.Am. J. Trop. Med. Hyg.200879462062310.4269/ajtmh.2008.79.620 18840754
     [Google Scholar]
  28. ReuterS.E. EvansA.M. ShakibS. LungershausenY. FrancisB. ValentiniG. BacchieriA. UbbenD. PaceS. Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin.Clin. Drug Investig.201535955956710.1007/s40261‑015‑0312‑8 26293519
     [Google Scholar]
  29. WhalenM.E. KajubiR. ChamankhahN. HuangL. OrukanF. WallenderE. KamyaM.R. DorseyG. JagannathanP. RosenthalP.J. MwebazaN. AweekaF.T. Reduced exposure to piperaquine, compared to adults, in young children receiving dihydroartemisinin-piperaquine as malaria chemoprevention.Clin. Pharmacol. Ther.201910661310131810.1002/cpt.1534 31173649
     [Google Scholar]
  30. TarningJ. RijkenM.J. McGreadyR. PhyoA.P. HanpithakpongW. DayN.P.J. WhiteN.J. NostenF. LindegardhN. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.Antimicrob. Agents Chemother.20125641997200710.1128/AAC.05756‑11 22252822
     [Google Scholar]
  31. KajubiR. HuangL. JagannathanP. ChamankhahN. WereM. RuelT. KossC.A. KakuruA. MwebazaN. KamyaM. HavlirD. DorseyG. RosenthalP.J. AweekaF.T. Antiretroviral therapy with efavirenz accentuates pregnancy-associated reduction of dihydroartemisinin-piperaquine exposure during malaria chemoprevention.Clin. Pharmacol. Ther.2017102352052810.1002/cpt.664 28187497
     [Google Scholar]
  32. BandaC.G. DzinjalamalaF. MukakaM. MallewaJ. MaidenV. TerlouwD.J. LallooD.G. KhooS.H. MwapasaV. Pharmacokinetics of piperaquine and safety profile of dihydroartemisinin-piperaquine co-administered with antiretroviral therapy in malaria-uninfected HIV-positive Malawian adults.Antimicrob. Agents Chemother.2018628e00634e1810.1128/AAC.00634‑18 29784846
     [Google Scholar]
  33. HungT.Y. DavisT.M.E. IlettK.F. Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection.J. Chromatogr B Analyt Technol Biomed. Life. Sci.20037911-29310110.1016/S1570‑0232(03)00209‑5 12798169
     [Google Scholar]
  34. LindegårdhN. AshtonM. BergqvistY. Automated solid-phase extraction method for the determination of piperaquine in whole blood by rapid liquid chromatography.Ther. Drug Monit.200325554455110.1097/00007691‑200310000‑00002 14508376
     [Google Scholar]
  35. TarningJ. SingtorojT. AnnerbergA. AshtonM. BergqvistY. WhiteN.J. DayN.P.J. LindegardhN. Development and validation of an automated solid phase extraction and liquid chromatographic method for the determination of piperaquine in urine.J. Pharm. Biomed. Anal.200641121321810.1016/j.jpba.2005.10.027 16311004
     [Google Scholar]
  36. LindegårdhN. WhiteN.J. DayN.P.J. High throughput assay for the determination of piperaquine in plasma.J. Pharm. Biomed. Anal.2005393-460160510.1016/j.jpba.2005.03.031 15905062
     [Google Scholar]
  37. LiuC. ZhangR. HongX. HuangT. MiS. WangN. Pharmacokinetics of piperaquine after single and multiple oral administrations in healthy volunteers.Yakugaku Zasshi2007127101709171410.1248/yakushi.127.1709 17917428
     [Google Scholar]
  38. ChoemangA. Na-BangchangK. An alternative HPLC with ultraviolet detection for determination of piperaquine in plasma.J. Chromatogr. Sci.2018571273210.1093/chromsci/bmy077 30169629
     [Google Scholar]
  39. SinghalP. GaurA. GautamA. VarshneyB. PaliwalJ. BatraV. Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma.J. Chromatogr B Analyt Technol Biomed. Life. Sci.20078591242910.1016/j.jchromb.2007.09.021 17923446
     [Google Scholar]
  40. LindegardhN. AnnerbergA. WhiteN.J. DayN.P.J. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.20088621-222723610.1016/j.jchromb.2007.12.011 18191623
     [Google Scholar]
  41. HodelE.M. ZanolariB. MercierT. BiollazJ. KeiserJ. OlliaroP. GentonB. DecosterdL.A. A single LC–tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.20098771086788610.1016/j.jchromb.2009.02.006 19249251
     [Google Scholar]
  42. KjellinL.L. DorseyG. RosenthalP.J. AweekaF. HuangL. Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC-MS/MS.Bioanalysis20146233081308910.4155/bio.14.254 25529877
     [Google Scholar]
  43. AzizM.Y. HoffmannK.J. AshtonM. LC–MS/MS quantitation of antimalarial drug piperaquine and metabolites in human plasma.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.2017106325325810.1016/j.jchromb.2017.06.035 28863865
     [Google Scholar]
  44. MwebazaN. CheahV. ForsmanC. KajubiR. MarzanF. WallenderE. DorseyG. RosenthalP.J. AweekaF. HuangL. Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations.PLoS One2020155e023389310.1371/journal.pone.0233893 32470030
     [Google Scholar]
  45. HuangL. SokV. Aslam-MirU. MarzanF. WhalenM. RosenthalP.J. AweekaF. Determination of unbound piperaquine in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry.J. Chromatogr. Open2022210004210.1016/j.jcoa.2022.100042 35531322
     [Google Scholar]
  46. BlessbornD. KaewkhaoN. TarningJ. A high-throughput LC-MS/MS assay for piperaquine from dried blood spots: Improving malaria treatment in resource-limited settings.J. Mass Spectrom. Adv. Clin. Lab202431192610.1016/j.jmsacl.2023.12.004 38229676
     [Google Scholar]
  47. RöshammarD. HaiT.N. Friberg HietalaS. Van HuongN. AshtonM. Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects.Eur. J. Clin. Pharmacol.200662533534110.1007/s00228‑005‑0084‑9 16570188
     [Google Scholar]
  48. ChinhN.T. QuangN.N. ThanhN.X. DaiB. GeueJ.P. AddisonR.S. TraversT. EdsteinM.D. Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects.Antimicrob. Agents Chemother.200953282883110.1128/AAC.00927‑08 19047656
     [Google Scholar]
  49. HanboonkunupakarnB. AshleyE.A. JittamalaP. TarningJ. PukrittayakameeS. HanpithakpongW. ChotsiriP. WattanakulT. PanapipatS. LeeS.J. DayN.P.J. WhiteN.J. Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects.Antimicrob. Agents Chemother.201458127340734610.1128/AAC.03704‑14 25267661
     [Google Scholar]
  50. QuangN.N. ChavchichM. AnhC.X. BirrellG.W. van BredaK. TraversT. RowcliffeK. EdsteinM.D. Comparison of the pharmacokinetics and ex vivo antimalarial activities of artesunate-amodiaquine and artemisinin-piperaquine in healthy volunteers for preselection malaria therapy.Am. J. Trop. Med. Hyg.2018991657210.4269/ajtmh.17‑0434 29741150
     [Google Scholar]
  51. ChotsiriP. GutmanJ.R. AhmedR. PoespoprodjoJ.R. SyafruddinD. KhairallahC. AsihP.B.S. L’lanzivaA. OtienoK. KariukiS. OumaP. WereV. KatanaA. PriceR.N. DesaiM. ter KuileF.O. TarningJ. Piperaquine pharmacokinetics during intermittent preventive treatment for malaria in pregnancy.Antimicrob. Agents Chemother.2021653e01150e2010.1128/AAC.01150‑20 33361303
     [Google Scholar]
  52. TarningJ. AshleyE.A. LindegardhN. StepniewskaK. PhaiphunL. DayN.P.J. McGreadyR. AshtonM. NostenF. WhiteN.J. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.Antimicrob. Agents Chemother.20085231052106110.1128/AAC.00955‑07 18180343
     [Google Scholar]
  53. NguyenD.V.H. NguyenQ.P. NguyenN.D. LeT.T.T. NguyenT.D. DinhD.N. NguyenT.X. BuiD. ChavchichM. EdsteinM.D. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.Antimicrob. Agents Chemother.20095383534353710.1128/AAC.01717‑08 19528277
     [Google Scholar]
  54. HoglundR.M. AdamI. HanpithakpongW. AshtonM. LindegardhN. DayN.P.J. WhiteN.J. NostenF. TarningJ. A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan.Malar. J.201211139810.1186/1475‑2875‑11‑398 23190801
     [Google Scholar]
  55. LonC. ManningJ.E. VanachayangkulP. SoM. SeaD. SeY. GosiP. LanteriC. ChaorattanakaweeS. SriwichaiS. ChannS. KuntawunginnW. BuathongN. NouS. WalshD.S. TynerS.D. JulianoJ.J. LinJ. SpringM. BethellD. KaewkungwalJ. TangD. ChuorC.M. SatharathP. SaundersD. Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: An open-label randomized trial.PLoS One201493e9313810.1371/journal.pone.0093138 24667662
     [Google Scholar]
  56. Millat-MartínezP. SalmanS. MooreB.R. BaroB. Page-SharpM. BattyK.T. RobinsonL.J. PomatW. KarunajeewaH. LamanM. ManningL. MitjàO. BassatQ. Piperaquine pharmacokinetic and pharmacodynamic profiles in healthy volunteers of Papua New Guinea after administration of three-monthly doses of dihydroartemisinin-piperaquine.Antimicrob. Agents Chemother.2022668e00185e2210.1128/aac.00185‑22 35862743
     [Google Scholar]
  57. TarningJ. LindegardhN. SandbergS. DayN.J.P. WhiteN.J. AshtonM. Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat.J. Pharm. Sci.20089783400341010.1002/jps.21226 17969131
     [Google Scholar]
  58. AshleyE.A. StepniewskaK. LindegardhN. AnnerbergA. TarningJ. McGreadyR. PhaiphunL. SinghasivanonP. WhiteN.J. NostenF. Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria.Eur. J. Clin. Pharmacol.201066770571210.1007/s00228‑010‑0804‑7 20300743
     [Google Scholar]
  59. RijkenM.J. McGreadyR. PhyoA.P. LindegardhN. TarningJ. LaochanN. ThanH.H. MuO. WinA.K. SinghasivanonP. WhiteN. NostenF. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.Antimicrob. Agents Chemother.201155125500550610.1128/AAC.05067‑11 21947392
     [Google Scholar]
  60. CroweA. IlettK.F. KarunajeewaH.A. BattyK.T. DavisT.M.E. Role of P glycoprotein in absorption of novel antimalarial drugs.Antimicrob. Agents Chemother.200650103504350610.1128/AAC.00708‑06 16917012
     [Google Scholar]
  61. LiuH. ZhouH. XingJ. The antiplasmodial activity of the carboxylic acid metabolite of piperaquine and its pharmacokinetic profiles in healthy volunteers.J. Antimicrob. Chemother.2024791788110.1093/jac/dkad349 37965893
     [Google Scholar]
  62. MooreB.R. BenjaminJ.M. AuyeungS.O. SalmanS. YadiG. GriffinS. Page-SharpM. BattyK.T. SibaP.M. MuellerI. RogersonS.J. DavisT.M.E. Safety, tolerability and pharmacokinetic properties of coadministered azithromycin and piperaquine in pregnant Papua New Guinean women.Br. J. Clin. Pharmacol.201682119921210.1111/bcp.12910 26889763
     [Google Scholar]
  63. AdamI. TarningJ. LindegardhN. MahgoubH. McGreadyR. NostenF. Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malaria.Am. J. Trop. Med. Hyg.2012871354010.4269/ajtmh.2012.11‑0410 22764289
     [Google Scholar]
  64. BenjaminJ.M. MooreB.R. SalmanS. Page-SharpM. TawatS. YadiG. LorryL. SibaP.M. BattyK.T. RobinsonL.J. MuellerI. DavisT.M.E. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.Antimicrob. Agents Chemother.20155974260427110.1128/AAC.00326‑15 25963981
     [Google Scholar]
  65. KarunajeewaH.A. IlettK.F. MuellerI. SibaP. LawI. Page-SharpM. LinE. LammeyJ. BattyK.T. DavisT.M.E. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.Antimicrob. Agents Chemother.200852123724310.1128/AAC.00555‑07 17967917
     [Google Scholar]
  66. TarningJ. ZongoI. SoméF.A. RouambaN. ParikhS. RosenthalP.J. HanpithakpongW. JongrakN. DayN.P.J. WhiteN.J. NostenF. OuedraogoJ-B. LindegardhN. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria.Clin. Pharmacol. Ther.201291349750510.1038/clpt.2011.254 22258469
     [Google Scholar]
  67. SalmanS. Page-SharpM. BattyK.T. KoseK. GriffinS. SibaP.M. IlettK.F. MuellerI. DavisT.M.E. Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.Antimicrob. Agents Chemother.20125663288329710.1128/AAC.06232‑11 22470119
     [Google Scholar]
  68. SambolN.C. YanL. CreekD.J. McCormackS.A. ArinaitweE. BigiraV. WanziraH. KakuruA. TapperoJ.W. LindegardhN. TarningJ. NostenF. AweekaF.T. ParikhS. Population pharmacokinetics of piperaquine in young Ugandan children treated with dihydroartemisinin-piperaquine for uncomplicated malaria.Clin. Pharmacol. Ther.2015981879510.1002/cpt.104 25732044
     [Google Scholar]
  69. XieY. LiuH. ChenX. XingJ. The effect of gastric pH on the pharmacokinetics-pharmacodynamics of naphthoquine in rodents, as well as in human predicted using a PBPK model.Curr. Drug Metab.202122536337110.2174/1389200222666210129102411 33511926
     [Google Scholar]
  70. MilandoF.A. JongoS. AbdullaS. NyaulingoG. TumboA.M. MswataS. TiagoJ. BongoleB.S. MiramboA. KassimuK. MbarakH. RashidM.A. HamadA. MihayoM. NdanziT. ZuberiO. SaadiaN. SombokaM. Yamba-YambaM. NgonyaniT. NditiA. MsuyaM. MwalimuB. MsuyaH.M. AwadhK. AliA. MarrastA.C. GossenD. NeequayeA. El-GaaloulM. RamachandruniH. Borghini-FuhrerI. Pharmacokinetics of a novel piperaquine dispersible granules formulation under fasting and various fed conditions versus piperaquine tablets when fasted in healthy Tanzanian adults: A randomized, phase I study.Clin. Transl. Sci.2025182e7013310.1111/cts.70133 39905737
     [Google Scholar]
  71. HaiT.N. HietalaS.F. Van HuongN. AshtonM. The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers.Acta Trop.2008107214514910.1016/j.actatropica.2008.05.013 18585670
     [Google Scholar]
  72. AnnerbergA. LwinK.M. LindegardhN. KhrutsawadchaiS. AshleyE. DayN.P.J. SinghasivanonP. TarningJ. WhiteN.J. NostenF. A small amount of fat does not affect piperaquine exposure in patients with malaria.Antimicrob. Agents Chemother.20115593971397610.1128/AAC.00279‑11 21709087
     [Google Scholar]
  73. TarningJ. LindegardhN. LwinK.M. AnnerbergA. KiricharoenL. AshleyE. WhiteN.J. NostenF. DayN.P.J. Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria.Antimicrob. Agents Chemother.20145842052205810.1128/AAC.02318‑13 24449770
     [Google Scholar]
  74. MooreB.R. BenjaminJ.M. SalmanS. GriffinS. GinnyE. Page-SharpM. RobinsonL.J. SibaP. BattyK.T. MuellerI. DavisT.M.E. Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.Antimicrob. Agents Chemother.201458105784579410.1128/AAC.03314‑14 25049242
     [Google Scholar]
  75. LwinK.M. PhyoA.P. TarningJ. HanpithakpongW. AshleyE.A. LeeS.J. CheahP. SinghasivanonP. WhiteN.J. LindegårdhN. NostenF. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria.Antimicrob. Agents Chemother.20125631571157710.1128/AAC.05877‑11 22252804
     [Google Scholar]
  76. MwebazaN. RohM.E. GengY.Z. OpioL. OpiraB. MarzanF. MwimaM.W. SsemukuyeT. GuoK. GingrichD. FotakiN. KakuruA. KizzaJ. AgutiM. AdramaH. KamyaM. DorseyG. RosenthalP.J. AweekaF.T. HuangL. Drug-drug interaction between dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine during malaria chemoprevention in pregnant women.Clin. Pharmacol. Ther.2025117250651410.1002/cpt.3471 39402742
     [Google Scholar]
  77. ChairatK. JittamalaP. HanboonkunupakarnB. PukrittayakameeS. HanpithakpongW. BlessbornD. WhiteN.J. DayN.P.J. TarningJ. Enantiospecific pharmacokinetics and drug–drug interactions of primaquine and blood-stage antimalarial drugs.J. Antimicrob. Chemother.201873113102311310.1093/jac/dky297 30085149
     [Google Scholar]
  78. AzizM.Y. HoffmannK.J. AshtonM. Inhibition of CYP3A by antimalarial piperaquine and its metabolites in human liver microsomes with IVIV extrapolation.J. Pharm. Sci.201810751461146710.1016/j.xphs.2018.01.009 29352982
     [Google Scholar]
  79. HanboonkunupakarnB. van der PluijmR.W. HoglundR. PukrittayakameeS. WinterbergM. MukakaM. WaithiraN. ChotivanichK. SinghasivanonP. WhiteN.J. DondorpA.M. TarningJ. JittamalaP. Sequential open-label study of the safety, tolerability, and pharmacokinetic interactions between dihydroartemisinin-piperaquine and mefloquine in healthy Thai adults.Antimicrob. Agents Chemother.2019638e00060e1910.1128/AAC.00060‑19 31182525
     [Google Scholar]
  80. LeongF.J. JainJ.P. FengY. GoswamiB. SteinD.S. WinnipsC. A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine.Malar. J.2018171710.1186/s12936‑017‑2162‑8 29304859
     [Google Scholar]
  81. KobylinskiK.C. JittamalaP. HanboonkunupakarnB. PukrittayakameeS. PantuwatanaK. PhasomkusolsilS. DavidsonS.A. WinterbergM. HoglundR.M. MukakaM. van der PluijmR.W. DondorpA. DayN.P.J. WhiteN.J. TarningJ. Safety, pharmacokinetics, and mosquito-lethal effects of ivermectin in combination with dihydroartemisinin-piperaquine and primaquine in healthy adult Thai subjects.Clin. Pharmacol. Ther.202010751221123010.1002/cpt.1716 31697848
     [Google Scholar]
  82. MinziO.M. MnkugweR.H. NgaimisiE. Kinung’hiS. HanssonA. PohankaA. KamuhabwaA. AklilluE. Effect of dihydroartemisinin-piperaquine on the pharmacokinetics of praziquantel for treatment of schistosoma mansoni infection.Pharmaceuticals202114540010.3390/ph14050400 33922522
     [Google Scholar]
  83. KuemmerleA. GossenD. JaninA. StokesA. AblaN. SzramowskaM. LorchU. El GaaloulM. Borghini-FuhrerI. ChalonS. Randomized, placebo‐controlled, double‐blind phase I trial of co‐administered pyronaridine and piperaquine in healthy adults of sub‐Saharan origin.Clin. Transl. Sci.2024174e1373810.1111/cts.13738 38594824
     [Google Scholar]
  84. BandaC.G. NkosiD. AllenE. WorkmanL. MadanitsaM. ChirwaM. KapululaM. MuyayaS. MunharoS. WiesnerL. PhiriK.S. MwapasaV. Ter KuileF.O. MaartensG. BarnesK.I. Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV.J. Antimicrob. Chemother.20227761733173710.1093/jac/dkac081 35288747
     [Google Scholar]
  85. HongH. Aslam-MirU. KajubiR. WallenderE. MwebazaN. DorseyG. RosenthalP.J. AweekaF.T. HuangL. Efavirenz-based antiretroviral therapy but not pregnancy increased unbound piperaquine exposure in women during malaria chemoprevention.Antimicrob. Agents Chemother.2023674e01427e2210.1128/aac.01427‑22 36916944
     [Google Scholar]
  86. ChotsiriP. WattanakulT. HoglundR.M. HanboonkunupakarnB. PukrittayakameeS. BlessbornD. JittamalaP. WhiteN.J. DayN.P.J. TarningJ. Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin–piperaquine in healthy volunteers.Br. J. Clin. Pharmacol.201783122752276610.1111/bcp.13372 28695570
     [Google Scholar]
  87. BandaC.G. NkosiD. AllenE. WorkmanL. MadanitsaM. ChirwaM. KapululaM. MuyayaS. MunharoS. TarningJ. PhiriK.S. MwapasaV. ter KuileF.O. MaartensG. BarnesK.I. Impact of dolutegravir-based antiretroviral therapy on piperaquine exposure following dihydroartemisinin-piperaquine intermittent preventive treatment of malaria in pregnant women living with HIV.Antimicrob. Agents Chemother.20226612e00584e2210.1128/aac.00584‑22 36374096
     [Google Scholar]
  88. Byakika-KibwikaP. SsenyongaR. LamordeM. BlessbornD. TarningJ. Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine.BMC Infect. Dis.2019191102510.1186/s12879‑019‑4647‑2 31795967
     [Google Scholar]
  89. MhangoE.K.G. SnorradottirB.S. KachingweB.H.K. KatunduK.G.H. GizurarsonS. Estimation of pediatric dosage of antimalarial drugs, using pharmacokinetic and physiological approach.Pharmaceutics2023154107610.3390/pharmaceutics15041076 37111562
     [Google Scholar]
  90. HoglundR.M. WorkmanL. EdsteinM.D. ThanhN.X. QuangN.N. ZongoI. OuedraogoJ.B. BorrmannS. MwaiL. NsanzabanaC. PriceR.N. DahalP. SambolN.C. ParikhS. NostenF. AshleyE.A. PhyoA.P. LwinK.M. McGreadyR. DayN.P.J. GuerinP.J. WhiteN.J. BarnesK.I. TarningJ. Population pharmacokinetic properties of piperaquine in falciparum malaria: An individual participant data meta-analysis.PLoS Med.2017141e100221210.1371/journal.pmed.1002212 28072872
     [Google Scholar]
  91. MluguE.M. MinziO.M.S. JohanssonM. KamuhabwaA.A.R. AklilluE. Pharmacokinetics of piperaquine and its association with intermittent malaria preventive therapy outcomes during pregnancy.BMC Pharmacol. Toxicol.20242513810.1186/s40360‑024‑00762‑6 38978151
     [Google Scholar]
  92. DingJ. HoglundR.M. TagborH. TintoH. ValéaI. MwapasaV. Kalilani-PhiriL. Van GeertruydenJ.P. NamboziM. MulengaM. HachizovuS. RavinettoR. D’AlessandroU. TarningJ. Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections.CPT Pharmacometrics Syst. Pharmacol.202413111893190310.1002/psp4.13211 39228131
     [Google Scholar]
  93. OlafuyiO. ColemanM. BadhanR.K.S. The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral‐mediated drug–drug interactions on piperaquine antimalarial therapy during pregnancy.Biopharm. Drug Dispos.201738846447810.1002/bdd.2087 28710808
     [Google Scholar]
  94. Pernaute-LauL. CamaraM. Nóbrega de SousaT. MorrisU. FerreiraM.U. GilJ.P. An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria.Expert Opin. Drug Metab. Toxicol.2022181395910.1080/17425255.2022.2049235 35285373
     [Google Scholar]
  95. Staehli HodelE.M. CsajkaC. ArieyF. GuidiM. KabanywanyiA.M. DuongS. DecosterdL.A. OlliaroP. BeckH.P. GentonB. Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.Antimicrob. Agents Chemother.201357295095810.1128/AAC.01700‑12 23229480
     [Google Scholar]
  96. LiuH. XieY. CaiT. XingJ. No effect of PXR (8055C>T) polymorphism on the pharmacokinetic profiles of piperaquine in healthy Chinese subjects.Curr. Drug Metab.202223216417010.2174/1389200223666220215151945 35168517
     [Google Scholar]
  97. LiuH. ZangM. YangA. JiJ. XingJ. Simultaneous determination of piperaquine and its N ‐oxidated metabolite in rat plasma using LC‐MS/MS.Biomed. Chromatogr.20173110e397410.1002/bmc.3974 28299804
     [Google Scholar]
  98. AblaN. HowgateE. Rowland-YeoK. DickinsM. Bergagnini-KolevM.C. ChenK.F. McFeelyS. BonnerJ.J. SantosL.G.A. GobeauN. BurtH. BarterZ. JonesH.M. WescheD. CharmanS.A. MöhrleJ.J. BurrowsJ.N. AlmondL.M. Development and application of a PBPK modeling strategy to support antimalarial drug development.CPT Pharmacometrics Syst. Pharmacol.20231291335134610.1002/psp4.13013 37587640
     [Google Scholar]
  99. TaskarK.S. HaradaI. AlluriR.V. Physiologically-based pharmacokinetic (PBPK) modelling of transporter mediated drug absorption, clearance and drug-drug interactions.Curr. Drug Metab.202122752353110.2174/1389200221999210101233340 33397250
     [Google Scholar]
  100. AlmondL.M. AbduljalilK. PansariA. KusmiderB. JonesH.M. Rowland YeoK. GardnerI. FaisalM. MarrastA.C. El GaaloulM. MöhrleJ.J. AblaN. PBPK-led assessment of antimalarial drug concentrations in breastmilk: A strategy for optimal use of prediction methods to guide decision making in an understudied population. CPT Pharmacometrics Syst. Pharmacol.2025psp4.13311.10.1002/psp4.1331139930940
     [Google Scholar]
  101. WarhurstD.C. CraigJ.C. AdaguI.S. GuyR.K. MadridP.B. FivelmanQ.L. Activity of piperaquine and other 4-aminoquinoline antiplasmodial drugs against chloroquine-sensitive and resistant blood-stages of Plasmodium falciparum.Biochem. Pharmacol.200773121910192610.1016/j.bcp.2007.03.011 17466277
     [Google Scholar]
/content/journals/cdm/10.2174/0113892002374755250613064601
Loading
A Comprehensive Review on the Pharmacokinetics and Bioanalysis of Piperaquine
Current Drug Metabolism 26, 93 (2025); https://doi.org/10.2174/0113892002374755250613064601
/content/journals/cdm/10.2174/0113892002374755250613064601
/content/journals/cdm/10.2174/0113892002374755250613064601
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): bioanalysis; LC-MS/MS; malaria; metabolism; pharmacokinetic; Piperaquine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test